Treating brain metastases in non-small cell lung cancer patients: what have we learnt from pharmaceutical recent clinical trials?

References

• Siegel RL, Miller KD, Jemal A. Cancer statistics, 2017. CA-Cancer J Clin. 2017;67:7–30.
   PubMed Web of Science ®Google Scholar
• Health Promotion Administration MOHAW, Executive Yuan, Taiwan. Cancer registry annual report, 2014 Taiwan. 2017 [cited 2017 Nov 11]. Available from: https://www.hpa.gov.tw/Pages/Detail.aspx?nodeid=269&pid=7330
   Google Scholar
• Nayak L, Lee EQ, Wen PY. Epidemiology of brain metastases. Curr Oncol Rep. 2012;14:48–54.
   PubMed Web of Science ®Google Scholar
• Shi AA, Digumarthy SR, Temel JS, et al. Does initial staging or tumor histology better identify asymptomatic brain metastases in patients with non-small cell lung cancer? J Thorac Oncol. 2006;1:205–210.
   PubMed Web of Science ®Google Scholar
• Rangachari D, Yamaguchi N, VanderLaan PA, et al. Brain metastases in patients with EGFR-mutated or ALK-rearranged non-small-cell lung cancers. Lung Cancer. 2015;88:108–111.
   PubMed Web of Science ®Google Scholar
• Gainor JF, Tseng D, Yoda S, et al. Patterns of metastatic spread and mechanisms of resistance to crizotinib in ROS1-positive non–small-cell lung cancer. JCO Precis Oncol. doi: 10.1200/PO.17.00063. Epub 2017 Aug 16.
   Web of Science ®Google Scholar
• NCCN Guidelines Version 9.2017 non-small cell lung cancer. National comprehensive cancer network website 2017. [cited 2017 Nov 11]. Available from: https://www.nccn.org/professionals/physician_gls/pdf/nscl.pdf
   Google Scholar
• Novello S, Barlesi F, Califano R, et al. Metastatic non-small-cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2016;27:v1–v27.
   PubMed Web of Science ®Google Scholar
• Reck M, Rabe KF. Precision diagnosis and treatment for advanced non–small-cell lung cancer. N Engl J Med. 2017;377:849–861.
   PubMed Web of Science ®Google Scholar
• Hanna N, Johnson D, Temin S, et al. Systemic therapy for stage IV non–small-cell lung cancer: American society of clinical oncology clinical practice guideline update. J Clin Oncol. 2017;35:3484–3515.
   PubMed Web of Science ®Google Scholar
• Maemondo M, Inoue A, Kobayashi K, et al. Gefitinib or chemotherapy for non–small-cell lung cancer with mutated EGFR. N Engl J Med. 2010;362:2380–2388.
   PubMed Web of Science ®Google Scholar
• Mitsudomi T, Morita S, Yatabe Y, et al. Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial. Lancet Oncol. 2010;11:121–128.
   PubMed Web of Science ®Google Scholar
• Rosell R, Carcereny E, Gervais R, et al. Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial. Lancet Oncol. 2012;13:239–246.
   PubMed Web of Science ®Google Scholar
• Sequist LV, Yang JC-H, Yamamoto N, et al. Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations. J Clin Oncol. 2013;31:3327–3334.
   PubMed Web of Science ®Google Scholar
• Yang JC-H, Hirsh V, Schuler M, et al. Symptom control and quality of life in LUX-Lung 3: a phase III study of afatinib or cisplatin/pemetrexed in patients with advanced lung adenocarcinoma with EGFR mutations. J Clin Oncol. 2013;31:3342–3350.
   PubMed Web of Science ®Google Scholar
• Solomon BJ, Mok TS, Kim D-W, et al. First-line crizotinib versus chemotherapy in ALK-positive lung cancer. N Engl J Med. 2014;371:2167–2177.
   PubMed Web of Science ®Google Scholar
• Soria J-C, Tan DSW, Chiari R, et al. First-line ceritinib versus platinum-based chemotherapy in advanced ALK-rearranged non-small-cell lung cancer (ASCEND-4): a randomised, open-label, phase 3 study. Lancet. 2017;389:917–929.
   PubMed Web of Science ®Google Scholar
• Peters S, Camidge DR, Shaw AT, et al. Alectinib versus crizotinib in untreated ALK-positive non–small-cell lung cancer. N Engl J Med. 2017;377:829–838.
   PubMed Web of Science ®Google Scholar
• Reck M, Rodríguez-Abreu D, Robinson AG, et al. Pembrolizumab versus chemotherapy for PD-L1–positive non–small-cell lung cancer. N Engl J Med. 2016;375:1823–1833.
   PubMed Web of Science ®Google Scholar
• NCCN Guidelines Version 1. 2017 central nervous system cancers. National comprehensive cancer network website 2017. [cited 2017 Nov 11]. Available from: https://www.nccn.org/professionals/physician_gls/pdf/cns.pdf
   Google Scholar
• Loganadane G, Hendriks L, Le Péchoux C, et al. The current role of whole brain radiation therapy in non–small cell lung cancer patients. J Thorac Oncol. 2017;12:1467–1477.
   PubMed Web of Science ®Google Scholar
• Kocher M, Soffietti R, Abacioglu U, et al. Adjuvant whole-brain radiotherapy versus observation after radiosurgery or surgical resection of one to three cerebral metastases: results of the EORTC 22952-26001 study. J Clin Oncol. 2011;29:134–141.
   PubMed Web of Science ®Google Scholar
• Mulvenna P, Nankivell M, Barton R, et al. Dexamethasone and supportive care with or without whole brain radiotherapy in treating patients with non-small cell lung cancer with brain metastases unsuitable for resection or stereotactic radiotherapy (QUARTZ): results from a phase 3, non-inferiority, randomised trial. Lancet. 2016;388:2004–2014.
   PubMed Web of Science ®Google Scholar
• Tsai P-F, Yang C-C, Chuang C-C, et al. Hippocampal dosimetry correlates with the change in neurocognitive function after hippocampal sparing during whole brain radiotherapy: a prospective study. Radiat Oncol. 2015;10:253.
   PubMed Web of Science ®Google Scholar
• Gondi V, Pugh SL, Tome WA, et al. Preservation of memory with conformal avoidance of the hippocampal neural stem-cell compartment during whole-brain radiotherapy for brain metastases (RTOG 0933): a phase II multi-institutional trial. J Clin Oncol. 2014;32:3810–3816.
   PubMed Web of Science ®Google Scholar
• Sperduto PW, Kased N, Roberge D, et al. Summary report on the graded prognostic assessment: an accurate and facile diagnosis-specific tool to estimate survival for patients with brain metastases. J Clin Oncol. 2012;30:419–425.
   PubMed Web of Science ®Google Scholar
• Sperduto PW, Yang T, Beal K, et al. Estimating survival in patients with lung cancer and brain metastases: an update of the graded prognostic assessment for lung cancer using molecular markers (lung-molgpa). JAMA Oncol. 2017;3:827–831.
   PubMed Web of Science ®Google Scholar
• Barlesi F, Gervais R, Lena H, et al. Pemetrexed and cisplatin as first-line chemotherapy for advanced non-small-cell lung cancer (NSCLC) with asymptomatic inoperable brain metastases: a multicenter phase II trial (GFPC 07-01). Ann Oncol. 2011;22:2466–2470.
   PubMed Web of Science ®Google Scholar
• Besse B, Le Moulec S, Maazieres J, et al. Bevacizumab in patients with non-squamous non-small-cell lung cancer and asymptomatic, untreated brain metastases (BRAIN): a non-randomised, phase II study. Clin Cancer Res. 2015;21:1896–1903.
   PubMed Web of Science ®Google Scholar
• Dinglin X-X, Huang Y, Liu H, et al. Pemetrexed and cisplatin combination with concurrent whole brain radiotherapy in patients with brain metastases of lung adenocarcinoma: a single-arm phase II clinical trial. J Neuro-Oncol. 2013;112:461–466.
   PubMed Web of Science ®Google Scholar
• Lim SH, Lee JY, Lee MY, et al. A randomized phase III trial of stereotactic radiosurgery (SRS) versus observation for patients with asymptomatic cerebral oligo-metastases in non-small-cell lung cancer. Ann Oncol. 2015;26:762–768.
   PubMed Web of Science ®Google Scholar
• Tan DSW, Mok TSK, Rebbeck TR. Cancer genomics: diversity and disparity across ethnicity and geography. J Clin Oncol. 2016;34:91–101.
   PubMed Web of Science ®Google Scholar
• Heon S, Yeap BY, Lindeman NI, et al. The impact of initial gefitinib or erlotinib versus chemotherapy on central nervous system progression in advanced non–small cell lung cancer with EGFR Mutations. Clin Cancer Res. 2012;18:4406–4414.
   PubMed Web of Science ®Google Scholar
• Iuchi T, Shingyoji M, Sakaida T, et al. Phase II trial of gefitinib alone without radiation therapy for Japanese patients with brain metastases from EGFR-mutant lung adenocarcinoma. Lung Cancer. 2013;82:282–287.
   PubMed Web of Science ®Google Scholar
• Arbour KC, Kris MG, Riely GJ, et al. Twice weekly pulse and daily continuous‐dose erlotinib as initial treatment for patients with epidermal growth factor receptor–mutant lung cancers and brain metastases. Cancer. 2018;124:105–109.
   PubMed Web of Science ®Google Scholar
• Seto T, Kato T, Nishio M, et al. Erlotinib alone or with bevacizumab as first-line therapy in patients with advanced non-squamous non-small-cell lung cancer harbouring EGFR mutations (JO25567): an open-label, randomised, multicentre, phase 2 study. Lancet Oncol. 2014;15:1236–1244.
   PubMed Web of Science ®Google Scholar
• Wu Y-L, Zhou C, C-P H, et al. Afatinib versus cisplatin plus gemcitabine for first-line treatment of Asian patients with advanced non-small-cell lung cancer harbouring EGFR mutations (LUX-Lung 6): an open-label, randomised phase 3 trial. Lancet Oncol. 2014;15:213–222.
   PubMed Web of Science ®Google Scholar
• Schuler M, Wu Y-L, Hirsh V, et al. First-line afatinib versus chemotherapy in patients with non–small cell lung cancer and common epidermal growth factor receptor gene mutations and brain metastases. J Thorac Oncol. 2016;11:380–390.
   PubMed Web of Science ®Google Scholar
• Park K, Tan E-H, O’Byrne K, et al. Afatinib versus gefitinib as first-line treatment of patients with EGFR mutation-positive non-small-cell lung cancer (LUX-Lung 7): a phase 2B, open-label, randomised controlled trial. Lancet Oncol. 2016;17:577–589.
   PubMed Web of Science ®Google Scholar
• Jänne PA, Yang JC-H, Kim D-W, et al. AZD9291 in EGFR inhibitor–resistant non–small-cell lung cancer. N Engl J Med. 2015;372:1689–1699.
   PubMed Web of Science ®Google Scholar
• Cross DAE, Ashton SE, Ghiorghiu S, et al. AZD9291, an irreversible EGFR TKI, overcomes T790M-mediated resistance to EGFR inhibitors in lung cancer. Cancer Discov. 2014;4:1046–1061.
   PubMed Web of Science ®Google Scholar
• Yang JC-H, Ahn M-J, D-W K, et al. Osimertinib in pretreated T790M-positive advanced non–small-cell lung cancer: AURA study phase II extension component. J Clin Oncol. 2017;35:1288–1296.
   PubMed Web of Science ®Google Scholar
• Mok TS, Wu Y-L, Ahn M-J, et al. Osimertinib or platinum–pemetrexed in EGFR T790M–positive lung cancer. N Engl J Med. 2017;376:629–640.
   PubMed Web of Science ®Google Scholar
• Goss G, Tsai C-M, Shepherd FA, et al. Osimertinib for pretreated EGFR Thr790Met-positive advanced non-small-cell lung cancer (AURA2): a multicentre, open-label, single-arm, phase 2 study. Lancet Oncol. 2016;17:1643–1652.
   PubMed Web of Science ®Google Scholar
• Ballard P, Yates JWT, Yang Z, et al. Preclinical comparison of osimertinib with other EGFR-TKIs in EGFR-mutant NSCLC brain metastases models, and early evidence of clinical brain metastases activity. Clin Cancer Res. 2016;22:5130–5140.
   PubMed Web of Science ®Google Scholar
• Goss G, Tsai C-M, Shepherd FA, et al. CNS response to osimertinib in patients with T790M-positive advanced NSCLC: pooled data from two phase II trials. Ann Oncol. 2018;29:687-693.
   PubMed Web of Science ®Google Scholar
• Mok TS, Ahn M-J, J-Y H, et al. CNS response to osimertinib in patients (pts) with T790M-positive advanced NSCLC: data from a randomized phase III trial (AURA3). J Clin Oncol. 2017;35:9005.
   Google Scholar
• Soria J-C, Ohe Y, Vansteenkiste J, et al. Osimertinib in untreated EGFR-mutated advanced non–small-cell lung cancer. N Engl J Med. 2018;378:113–125.
   PubMed Web of Science ®Google Scholar
• Vansteenkiste J, Reungwetwattana T, Nakagawa K, et al. LBA5 CNS response to osimertinib vs standard of care (SoC) EGFR-TKI as first-line therapy in patients (pts) with EGFR-TKI sensitising mutation (EGFRm)-positive advanced non-small cell lung cancer (NSCLC): data from the FLAURA study. Ann Oncol. 2017;28:mdx729.007-mdx729.007.
   PubMed Web of Science ®Google Scholar
• Zeng Q, Wang J, Cheng Z, et al. Discovery and evaluation of clinical candidate AZD3759, a potent, oral active, central nervous system-penetrant, epidermal growth factor receptor tyrosine kinase inhibitor. J Med Chem. 2015;58:8200–8215.
   PubMed Web of Science ®Google Scholar
• Ahn M-J, Kim D-W, Cho BC, et al. Activity and safety of AZD3759 in EGFR-mutant non-small-cell lung cancer with CNS metastases (BLOOM): a phase 1, open-label, dose-escalation and dose-expansion study. Lancet Resp Med. 2017;5:891–902.
   PubMed Web of Science ®Google Scholar
• Doherty MK, Korpanty GJ, Tomasini P, et al. Treatment options for patients with brain metastases from EGFR/ALK-driven lung cancer. Radiother Oncol. 2017;123:195–202.
   PubMed Web of Science ®Google Scholar
• Magnuson WJ, Lester-Coll NH, Wu AJ, et al. Management of brain metastases in tyrosine kinase inhibitor–naïve epidermal growth factor receptor–mutant non–small-cell lung cancer: a retrospective multi-institutional analysis. J Clin Oncol. 2017;35:1070–1077.
   PubMed Web of Science ®Google Scholar
• Yang W-C, Xiao F, J-Y S, et al. Epidermal growth factor receptor mutation predicts favorable outcomes in non-small cell lung cancer patients with brain metastases treated with stereotactic radiosurgery. Radiother Oncol. 2017 [cited 2017 Oct 27]. doi:10.1016/j.radonc.2017.10.010.
   Web of Science ®Google Scholar
• Chuan Tang S, Nguyen LN, Sparidans RW, et al. Increased oral availability and brain accumulation of the ALK inhibitor crizotinib by coadministration of the P-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2) inhibitor elacridar. Int J Cancer. 2014;134:1484–1494.
   PubMed Web of Science ®Google Scholar
• Solomon BJ, Cappuzzo F, Felip E, et al. Intracranial efficacy of crizotinib versus chemotherapy in patients with advanced ALK-positive non–small-cell lung cancer: results from PROFILE 1014. J Clin Oncol. 2016;34:2858–2865.
   PubMed Web of Science ®Google Scholar
• Ng TL, Camidge DR. Intracranial efficacy of crizotinib versus chemotherapy in PROFILE 1014: shining a light on central nervous system endpoints in clinical trials. Transl Cancer Res. 2016;5:S520–S525.
   Web of Science ®Google Scholar
• Costa DB, Shaw AT, S-Hi O, et al. Clinical experience with crizotinib in patients with advanced ALK-rearranged non–small-cell lung cancer and brain metastases. J Clin Oncol. 2015;33:1881–1888.
   PubMed Web of Science ®Google Scholar
• Weickhardt AJ, Scheier B, Burke JM, et al. Local ablative therapy of oligoprogressive disease prolongs disease control by tyrosine kinase inhibitors in oncogene-addicted non–small-cell lung cancer. J Thorac Oncol. 2012;7:1807–1814.
   PubMed Web of Science ®Google Scholar
• Kort A, Sparidans RW, Wagenaar E, et al. Brain accumulation of the EML4-ALK inhibitor ceritinib is restricted by P-glycoprotein (P-GP/ABCB1) and breast cancer resistance protein (BCRP/ABCG2). Pharmacol Res. 2015;102:200–207.
   PubMed Web of Science ®Google Scholar
• Kim D-W, Mehra R, Tan DSW, et al. Activity and safety of ceritinib in patients with ALK-rearranged non-small-cell lung cancer (ASCEND-1): updated results from the multicentre, open-label, phase 1 trial. Lancet Oncol. 2016;17:452–463.
   PubMed Web of Science ®Google Scholar
• Felip E, Orlov S, Park K, et al. Phase 2 study of ceritinib in ALKi-naïve patients (pts) with ALK-rearranged (ALK+) non-small cell lung cancer (NSCLC): whole body responses in the overall pt group and in pts with baseline brain metastases (BM). Ann Oncol. 2016;27:1208O–1208O.
   Web of Science ®Google Scholar
• Shaw AT, Kim TM, Crinò L, et al. Ceritinib versus chemotherapy in patients with ALK-rearranged non-small-cell lung cancer previously given chemotherapy and crizotinib (ASCEND-5): a randomised, controlled, open-label, phase 3 trial. Lancet Oncol. 2017;18:874–886.
   PubMed Web of Science ®Google Scholar
• Cho BC, Kim D-W, Bearz A, et al. ASCEND-8: A randomized phase 1 study of ceritinib, 450 mg or 600 mg, taken with a low-fat meal versus 750 mg in fasted state in patients with anaplastic lymphoma kinase (ALK)-rearranged metastatic non–small cell lung cancer (NSCLC). J Thorac Oncol. 2017;12:1357–1367.
   PubMed Web of Science ®Google Scholar
• Cho BC, Obermannová R, Bearz A, et al. OA 05.07 efficacy and updated safety of ceritinib (450 mg or 600 mg) with low-fat meal vs 750 mg fasted in ALK+ metastatic NSCLC. J Thorac Oncol. 2017;12:S1757.
   Web of Science ®Google Scholar
• Kodama T, Hasegawa M, Takanashi K, et al. Antitumor activity of the selective ALK inhibitor alectinib in models of intracranial metastases. Cancer Chemother Pharmacol. 2014;74:1023–1028.
   PubMed Web of Science ®Google Scholar
• Gandhi L, Ou S-HI, Shaw AT, et al. Efficacy of alectinib in central nervous system metastases in crizotinib-resistant ALK-positive non–small-cell lung cancer: comparison of RECIST 1.1 and RANO-HGG criteria. Eur J Cancer. 2017;82:27–33.
   PubMed Web of Science ®Google Scholar
• Lin NU, Lee EQ, Aoyama H, et al. Response assessment criteria for brain metastases: proposal from the RANO group. Lancet Oncol. 2015;16:e270–e278.
   PubMed Web of Science ®Google Scholar
• Lin NU, Prowell T, Tan AR, et al. Modernizing clinical trial eligibility criteria: recommendations of the American society of clinical oncology–friends of cancer research brain metastases working group. J Clin Oncol. 2017;35:3760–3773.
   PubMed Web of Science ®Google Scholar
• Novello S, Mazieres J, Oh IJ, et al. 1299O_PR primary results from the phase III ALUR study of alectinib versus chemotherapy in previously treated ALK+ non-small-cell lung cancer (NSCLC). Ann Oncol. 2017;28:mdx440.058-mdx440.058.
   Web of Science ®Google Scholar
• De Castro J, Novello S, Mazieres J, et al. 1346P CNS efficacy results from the phase III ALUR study of alectinib vs chemotherapy in previously treated ALK+ NSCLC. Ann Oncol. 2017;28:mdx380.048-mdx380.048.
   Web of Science ®Google Scholar
• Gadgeel S, Peters S, Mok TSK, et al. 1298O_PR alectinib vs crizotinib in treatment-naïve ALK+ NSCLC: CNS efficacy results from the ALEX study. Ann Oncol. 2017;28:mdx440.057-mdx440.057.
   Web of Science ®Google Scholar
• Ou S-HI, Tiseo M, Camidge DR, et al. 1345P Intracranial efficacy of brigatinib (BRG) in patients (Pts) with crizotinib (CRZ)-refractory anaplastic lymphoma kinase (ALK)-positive non-small cell lung cancer (NSCLC) and baseline CNS metastases. Ann Oncol. 2017;28:mdx380.047-mdx380.047.
   PubMed Web of Science ®Google Scholar
• Ahn M-J, Camidge DR, Tiseo M, et al. OA 05.05 brigatinib in crizotinib-refractory ALK+ NSCLC: updated efficacy and safety results from ALTA, a randomized phase 2 trial. J Thorac Oncol. 2017;12:S1755–S1756.
   PubMed Web of Science ®Google Scholar
• Solomon BJ, Shaw AT, S-Hi O, et al. OA 05.06 Phase 2 study of lorlatinib in patients with advanced ALK+/ROS1+ non-small-cell lung cancer. J Thorac Oncol. 2017;12:S1756.
   Web of Science ®Google Scholar
• Gettinger SN, Bazhenova LA, Langer CJ, et al. Activity and safety of brigatinib in ALK-rearranged non-small-cell lung cancer and other malignancies: a single-arm, open-label, phase 1/2 trial. Lancet Oncol. 2016;17:1683–1696.
   PubMed Web of Science ®Google Scholar
• Shaw AT, Felip E, Bauer TM, et al. Lorlatinib in non-small-cell lung cancer with ALK or ROS1 rearrangement: an international, multicentre, open-label, single-arm first-in-man phase 1 trial. Lancet Oncol. 2017;18:1590–1599.
   PubMed Web of Science ®Google Scholar
• Quail DF, Joyce JA. The microenvironmental landscape of brain tumors. Cancer Cell. 2017;31:326–341.
   PubMed Web of Science ®Google Scholar
• Iwasaki A. Immune regulation of antibody access to neuronal tissues. Trends Mol Med. 2017;23:227–245.
   PubMed Web of Science ®Google Scholar
• Berghoff AS, Fuchs E, Ricken G, et al. Density of tumor-infiltrating lymphocytes correlates with extent of brain edema and overall survival time in patients with brain metastases. OncoImmunology. 2016;5:e1057388.
   PubMed Web of Science ®Google Scholar
• Harter PN, Bernatz S, Scholz A, et al. Distribution and prognostic relevance of tumor-infiltrating lymphocytes (TILs) and PD-1/PD-L1 immune checkpoints in human brain metastases. Oncotarget. 2015;6:40836–40849.
   PubMed Web of Science ®Google Scholar
• Téglási V, Reiniger L, Fábián K, et al. Evaluating the significance of density, localization, and PD-1/PD-L1 immunopositivity of mononuclear cells in the clinical course of lung adenocarcinoma patients with brain metastasis. Neuro-Oncol. 2017;19:1058–1067.
   PubMed Web of Science ®Google Scholar
• Pinato DJ, Shiner RJ, White SDT, et al. Intra-tumoral heterogeneity in the expression of programmed-death (PD) ligands in isogeneic primary and metastatic lung cancer: implications for immunotherapy. OncoImmunology. 2016;5:e1213934.
   PubMed Web of Science ®Google Scholar
• Tan AC, Heimberger AB, Menzies AM, et al. Immune checkpoint inhibitors for brain metastases. Curr Oncol Rep. 2017;19:38.
   PubMed Web of Science ®Google Scholar
• Herbst RS, Baas P, D-W K, et al. Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial. Lancet. 2016;387:1540–1550.
   PubMed Web of Science ®Google Scholar
• Brahmer J, Reckamp KL, Baas P, et al. Nivolumab versus docetaxel in advanced squamous-cell non–small-cell lung cancer. N Engl J Med. 2015;373:123–135.
   PubMed Web of Science ®Google Scholar
• Borghaei H, Paz-Ares L, Horn L, et al. Nivolumab versus docetaxel in advanced nonsquamous non–small-cell lung cancer. N Engl J Med. 2015;373:1627–1639.
   PubMed Web of Science ®Google Scholar
• Rittmeyer A, Barlesi F, Waterkamp D, et al. Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial. Lancet. 2017;389:255–265.
   PubMed Web of Science ®Google Scholar
• Goldberg SB, Gettinger SN, Mahajan A, et al. Pembrolizumab for patients with melanoma or non-small-cell lung cancer and untreated brain metastases: early analysis of a non-randomised, open-label, phase 2 trial. Lancet Oncol. 2016;17:976–983.
   PubMed Web of Science ®Google Scholar
• Gauvain C, Vauléon E, Chouaid C, et al. Intracerebral efficacy and tolerance of nivolumab in non–small-cell lung cancer patients with brain metastases. Lung Cancer. 2018;116:62–66.
   PubMed Web of Science ®Google Scholar
• Kanai O, Fujita K, Okamura M, et al. Severe exacerbation or manifestation of primary disease related to nivolumab in non-small-cell lung cancer patients with poor performance status or brain metastases. Ann Oncol. 2016;27:1354–1356.
   PubMed Web of Science ®Google Scholar
• Dudnik E, Yust-Katz S, Nechushtan H, et al. Intracranial response to nivolumab in NSCLC patients with untreated or progressing CNS metastases. Lung Cancer. 2016;98:114–117.
   PubMed Web of Science ®Google Scholar
• Goldman JW, Crino L, Vokes EE, et al. Nivolumab (nivo) in patients (pts) with advanced (adv) NSCLC and central nervous system (CNS) metastases (mets). J Clin Oncol. 2016;34:9038.
   Google Scholar
• Lukas RV, Gandhi M, O’Hear C, et al. 81O Safety and efficacy analyses of atezolizumab in advanced non-small cell lung cancer (NSCLC) patients with or without baseline brain metastases. Ann Oncol. 2017;28:mdx091.001-mdx091.001.
   Web of Science ®Google Scholar
• Schoenhals JE, Seyedin SN, Anderson C, et al. Uncovering the immune tumor microenvironment in non-small cell lung cancer to understand response rates to checkpoint blockade and radiation. Transl Lung Cancer Res. 2017;6:148–158.
   PubMed Web of Science ®Google Scholar
• Gong X, Li X, Jiang T, et al. Combined radiotherapy and anti–PD-L1 antibody synergistically enhances antitumor effect in non–small cell lung cancer. J Thorac Oncol. 2017;12:1085–1097.
   PubMed Web of Science ®Google Scholar
• Takamori S, Toyokawa G, Takada K, et al. Combination therapy of radiotherapy and anti-PD-1/PD-L1 treatment in non–small-cell lung cancer: a mini-review. Clin Lung Cancer. 2018;19:12–16.
   PubMed Web of Science ®Google Scholar
• Colaco RJ, Martin P, Kluger HM, et al. Does immunotherapy increase the rate of radiation necrosis after radiosurgical treatment of brain metastases? J Neurosurg. 2016;125:17–23.
   PubMed Web of Science ®Google Scholar
• Cohen JV, Kluger HM. Systemic immunotherapy for the treatment of brain metastases. Front Oncol. 2016;6:49.
   PubMed Web of Science ®Google Scholar
• Qian JM, Mahajan A, Yu JB, et al. Comparing available criteria for measuring brain metastasis response to immunotherapy. J Neuro-Oncol. 2017;132:479–485.
   PubMed Web of Science ®Google Scholar